Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1/2 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 5Lymphoid 5Breast 4Thoracic 3Classical hematology 3Plasma cell 2Other solid neoplasm 1Myeloid 1Gynecologic 1

Conditions

Neutropenia 3Febrile Neutropenia 3Breast Neoplasms 2Thoracic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 58Busulfan 47fludarabine phosphate 45Cyclosporine 34Mycophenolic Acid 31Whole-Body Irradiation 29Peripheral Blood Stem Cell Transplantation 29fludarabine 27Antilymphocyte Serum 27Tacrolimus 26Methotrexate 25Melphalan 25Filgrastim 20Radiotherapy 19Darbepoetin alfa 19Cytarabine 19Cord Blood Stem Cell Transplantation 18Epoetin Alfa 17Granulocyte Colony-Stimulating Factor 14Methylprednisolone 13thymoglobulin 10Thiotepa 9Etoposide 9Alemtuzumab 9eltrombopag 8Stem Cell Transplantation 8olaparib 7sargramostim 6hetrombopag 6Rituximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × pegylated granulocyte colony-stimulating factor × Classical hematology × Clear all
NCT07205536 2025-12-11

ANC-IIT-004

Affiliated Hospital of Nantong University

Phase 2 Recruiting
30 enrolled
Classical hematologyThoracic

Neutropenia, Thoracic Neoplasms, Febrile Neutropenia

NCT02005458 2018-07-17

Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy

Xiamen Amoytop Biotech Co., Ltd.

Phase 2 Completed
80 enrolled
BreastClassical hematologyThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neutropenia, Febrile Neutropenia

NCT02119715 2014-04-22

A Phase II Study Comparing Pegylated rhG-CSF(HHPG-19K) and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
182 enrolled
BreastClassical hematology

Breast Neoplasms, Neutropenia, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡